



Celldex Therapeutics, Inc.  
Investor Relations Department  
119 Fourth Avenue  
Needham, MA 02494-2725  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

<b>NASDAQ: CLDX</b> <sup>1</sup>	
Last Trade:	2.47
Trade Time:	4:00 PM ET Mar 16, 2018
Change:	-0.02  (0.803%)
Day Range	2.43 - 2.49
52-Week Range	2.20 - 3.75
Volume	1,912,333
Market Cap. (\$M)	0.00
Shares Out (M)	0.00

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Mar 7, 2018*  
[Celldex Provides Corporate Update and Reports Full Year 2017 Results](#)
- Mar 2, 2018*  
[Celldex to Report Fourth Quarter and Year-End 2017 Business/Financial Results and Present at Upcoming Investor Conference](#)
- Nov 30, 2017*  
[Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors](#)
- Nov 17, 2017*  
[Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma](#)
- Nov 7, 2017*  
[Celldex Reports Third Quarter 2017 Results](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

### [Fourth Quarter Financial Results](#)

- Mar 7, 2018*  
[Annual Report \(10-K\)](#)
- Apr 28, 2017*  
[Definitive Proxy Statement](#)
- Nov 7, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*  
[Quarterly Report \(10-Q\)](#)